ArticleBiochemistry and biophysics reports2025
Serum-soluble SDC1 in septic patients is rich in heparan sulfate, which affects the ELISA quantification values.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between serum lipid-apolipoprotein alterations and soluble syndecan-1 dynamics in sepsis: impact of apolipoprotein E isoforms.Biochemistry and biophysics reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Soluble syndecan (sSDC) 1, which is released into the blood by shedding of the SDC1 ectodomain, is a potent biomarker of various inflammatory diseases and cancers. However, the characteristics of serum sSDC1 and methods for its quantification have not been thoroughly investigated. We investigated the properties of sSDC1 in the serum of patients with sepsis and their effects on measurement values. Methods: Serum sSDC1 levels in patients with and without sepsis were determined using dot blot analysis and enzyme-linked immunosorbent assay (ELISA). The molecular characteristics of serum sSDC1 were evaluated using western blotting and immunoprecipitation. Results: Serum sSDC1 ELISA values were more clearly able to distinguish between septic and non-septic patients than dot blot intensities. Serum sSDC1 mainly exists as the derivatives of the SDC1 ectodomain with molecular masses of 150-200 and 75 kDa, which were more prevalent in septic patients than non-septic patients. The former derivatives showed significant susceptibility to heparinase III. The presence of high-molecular-weight sSDC1 (>200 kDa), immunoprecipitated with an anti-heparan sulfate (HS) antibody, was also characteristic of the serum of patients with sepsis. The 150-200 and 75 kDa forms may have been derived from this high-molecular-weight HS-rich sSDC1. Importantly, the serum sSDC1 ELISA values for patients with sepsis showed a significant increase after treatment with heparinase III. Conclusions: sSDC1 molecules generated by sepsis-induced pathological shedding may be rich in HS and heterogeneous compared to those generated by physiological shedding. The HS content affected the ELISA quantification values of serum sSDC1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.